Klebsiella pneumoniae Infections - Pipeline Review, H1 2018

  • ID: 4518486
  • Report
  • 110 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Appili Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • LegoChem Biosciences Inc
  • Nosopharm SAS
  • Phico Therapeutics Ltd
  • MORE
Klebsiella pneumoniae Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2018, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights:

This latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 26 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Appili Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • LegoChem Biosciences Inc
  • Nosopharm SAS
  • Phico Therapeutics Ltd
  • MORE
Introduction

Report Coverage

Klebsiella pneumoniae Infections - Overview

Klebsiella pneumoniae Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Klebsiella pneumoniae Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Klebsiella pneumoniae Infections - Drug Profiles

Antibodies for Klebsiella pneumoniae Infections - Drug Profile

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile

ASN-300 - Drug Profile

ATI-1503 - Drug Profile

Biologics for Bacterial Infections - Drug Profile

C-3JEPXX - Drug Profile

CA-824 - Drug Profile

CC-1807 - Drug Profile

cefiderocol sulfate tosylate - Drug Profile

Debio-1454 - Drug Profile

DS-86760016 - Drug Profile

EBX-004 - Drug Profile

EVXB-2 - Drug Profile

FG-LpxC - Drug Profile

FPI-1465 - Drug Profile

GN Snare - Drug Profile

GYR-12 - Drug Profile

IBN-1 - Drug Profile

kelokardin - Drug Profile

Klebsiella pneumonia vaccine - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

Klebsiella pneumoniae vaccine - Drug Profile

LCB-180055 - Drug Profile

Monoclonal Antibodies to Inhibit Carbapenemase for Klebsiella pneumoniae and Acinetobacter baumannii Infections - Drug Profile

NCL-195 - Drug Profile

NOSO-502 - Drug Profile

NOSO-95179 - Drug Profile

Onc-72 - Drug Profile

OTP-602 - Drug Profile

Peptides for Infectious Diseases - Drug Profile

PT-4 - Drug Profile

Recombinant Enzyme to Disrupt Bacterial Cell Wall for Gram Negative Bacterial Infections - Drug Profile

RX-04 - Drug Profile

RXP-873 - Drug Profile

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile

Small Molecules for Bacterial and Fungal Infections - Drug Profile

Small Molecules for Bacterial Infections - Drug Profile

Small Molecules for Bacterial Infections - Drug Profile

Small Molecules for Klebsiella pneumoniae Infections - Drug Profile

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Small Molecules to Inhibit KasA for Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Small Molecules to Inhibit Lipopolysaccharide for Bacterial and Nosocomial Infections - Drug Profile

SPR-741 - Drug Profile

tebipenem pivoxil - Drug Profile

TP-6076 - Drug Profile

VRP-001 - Drug Profile

VXD-004 - Drug Profile

WLBU-2 - Drug Profile

Klebsiella pneumoniae Infections - Dormant Projects

Klebsiella pneumoniae Infections - Discontinued Products

Klebsiella pneumoniae Infections - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H1 2018

Klebsiella pneumoniae Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by C3J Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H1 2018

Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by LegoChem Biosciences Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Vaxdyn SL, H1 2018

Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H1 2018

Klebsiella pneumoniae Infections - Dormant Projects, H1 2018

Klebsiella pneumoniae Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018

Klebsiella pneumoniae Infections - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ABAC Therapeutics SA
  • Acies Bio doo
  • AmpliPhi Biosciences Corp
  • Appili Therapeutics Inc
  • C3J Therapeutics Inc
  • ContraFect Corp
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • LegoChem Biosciences Inc
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Pfizer Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Vaxdyn SL
  • Venus Medicine Research Center
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll